AI helped design a vaccine intended to work against entire coronavirus families, not just the strain it was built for, and its first human trial just came back safe.
Researchers at the University of Cambridge used AI to scan thousands of viruses in the sarbecovirus family - which includes SARS, COVID-19, and related bat coronaviruses that could jump to humans - and identify genetic features that evolution has left largely unchanged across strains. Those conserved features became the blueprint for a DNA vaccine, which is more shelf-stable than the mRNA shots used during the pandemic and can be delivered without needles via a high-pressure liquid injection system. In its first human trial, the vaccine stimulated antibodies capable of recognizing multiple types of sarbecoviruses and was deemed safe and well-tolerated. The caveat: the researchers themselves describe the immune responses as modest, and larger trials are still needed to determine whether the vaccine can actually prevent infection.
The real advance here is the design method, not the result. Traditional vaccines target one known strain; AI's value is finding what a virus can't easily mutate away from, across thousands of variants at once. If that targeting logic holds up in larger trials, it could shift pandemic preparedness from reactive - chase the new variant after the outbreak starts - to anticipatory.
A universal vaccine is still years away, this trial was small, and "modest immune response" is a considerable distance from the efficacy threshold regulators require. But for the first time, the framework for getting there is becoming concrete.